2026-04-17T12:10:26Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4702132025-10-28T11:02:23Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Mirelis, Jesús G. author Escobar-Lopez, Luis author Ochoa, Juan Pablo author Espinosa, Maria Angeles author Villacorta, Eduardo author Navarro Peñalver, Marina author Casas, Guillem author Mora-Ayestarán, Nerea author Barriales-Villa, Roberto author Mogollón-Jiménez, María Victoria author García-Pinilla, José Manuel author García-Granja, Pablo Elpidio author Climent, Vicente author Palomino-Doza, Julian author García-Álvarez, Ana author Álvarez-Barredo, María author Cabrera-Borrego, Eva author Ripoll-Vera, Tomás author Peña-Peña, María Luisa author Rodríguez-González, Elena author Gallego-Delgado, María author Gonzalez-Carrillo, Josefa author Fernández-Ávila, Ana author Rodríguez Palomares, José F author Brugada, Ramon author Bayés-Genís, Antoni author Dominguez, Fernando author García-Pavía, Pablo author Universitat Autònoma de Barcelona author 2022 Genotype and left ventricular scar on cardiac magnetic resonance (CMR) are increasingly recognized as risk markers for adverse outcomes in non-ischaemic dilated cardiomyopathy (DCM). We investigated the combined influence of genotype and late gadolinium enhancement (LGE) in assessing prognosis in a large cohort of patients with DCM. Outcomes of 600 patients with DCM (53.3 ± 14.1 years, 66% male) who underwent clinical CMR and genetic testing were retrospectively analysed. The primary endpoints were end-stage heart failure (ESHF) and malignant ventricular arrhythmias (MVA). During a median follow-up of 2.7 years (interquartile range 1.3-4.9), 24 (4.00%) and 48 (8.00%) patients had ESHF and MVA, respectively. In total, 242 (40.3%) patients had pathogenic/likely pathogenic variants (positive genotype) and 151 (25.2%) had LGE. In survival analysis, positive LGE was associated with MVA and ESHF (both, p < 0.001) while positive genotype was associated with ESHF (p = 0.034) but not with MVA (p = 0.102). Classification of patients according to genotype (G+/G-) and LGE presence (L+/L-) revealed progressively increasing events across L-/G-, L-/G+, L+/G- and L+/G+ groups and resulted in optimized MVA and ESHF prediction (p < 0.001 and p = 0.001, respectively). Hazard ratios for MVA and ESHF in patients with either L+ or G+ compared with those with L-/G- were 4.71 (95% confidence interval: 2.11-10.50, p < 0.001) and 7.92 (95% confidence interval: 1.86-33.78, p < 0.001), respectively. Classification of patients with DCM according to genotype and LGE improves MVA and ESHF prediction. Scar assessment with CMR and genotyping should be considered to select patients for primary prevention implantable cardioverter-defibrillator placement. Non-ischaemic dilated cardiomyopathy (NI DCM) patients with positive genotype and/or late gadolinium enhancement (LGE) show increased risk of ventricular arrhythmias and end-stage heart failure (ESHF) during follow-up. CI, confidence interval; HR, hazard ratio; LVEF, left ventricular ejection fraction; MVA, malignant ventricular arrhythmia. Cardiac magnetic resonance Dilated cardiomyopathy End-stage heart failure Genotype Late gadolinium enhancement Sudden cardiac death Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy